Translational Research for Developing Blood-Based Biomarkers of Sarcopenia

22 Mar 2026 11:20 11:40
Beom-Jun KimSouth Korea Speaker Translational Research for Developing Blood-Based Biomarkers of SarcopeniaSarcopenia, characterized by the progressive loss of skeletal muscle mass and function, is a major determinant of frailty and adverse health outcomes in aging populations. Consequently, the identification of reliable blood-based biomarkers is critical for early diagnosis, risk stratification, and the development of therapeutic interventions. This lecture provides an overview of our translational research efforts aimed at discovering and validating novel biomarkers using multi-omics approaches in both preclinical and clinical models of sarcopenia. In animal models, we have integrated proteomics and metabolomics to identify candidate biomarkers reflecting key pathophysiological mechanisms of muscle degeneration. Concurrently, in human cohorts, we employed multi-omics profiling of circulating biomarkers to detect signatures associated with muscle mass, strength, and physical performance. A central focus of our research is the cross-validation of these biomarkers between animal and human models to ensure translational relevance. By leveraging comparative bioinformatics analyses, we aim to establish robust biomarkers with high sensitivity and specificity for detecting sarcopenia and monitoring disease progression. Furthermore, this lecture will discuss the potential clinical utility of these biomarkers in personalized risk assessment. By bridging preclinical discoveries with human validation studies, our work contributes to the advancement of precision medicine for sarcopenia. Ultimately, establishing reliable blood-based biomarkers will facilitate the early identification of high-risk individuals, improve patient stratification in clinical trials, and enable targeted therapeutic strategies.